Inari Medical Receives National Reimbursement Approval for ClotTriever Thrombectomy System in Japan

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering fr...

December 03, 2024 | Tuesday | News
Renalys Pharma's Sparsentan Receives Orphan Drug Designation for Primary IgA Nephropathy in Japan

Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Trav...

December 02, 2024 | Monday | News
Ascentage Pharma’s Olverembatinib Gains Expanded Inclusion in China’s 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...

November 29, 2024 | Friday | News
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Shows 96% Efficacy in Phase 3 PURPOSE 2 Trial

Gilead Sciences, Inc. (Nasdaq: GILD) announced The New England Journal of Medicine ( NEJM ) published the full results from the co...

November 28, 2024 | Thursday | News
Acadia Pharmaceuticals Licenses SAN711 from Saniona for Essential Tremor, Expanding Neurology Pipeline

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the develo...

November 27, 2024 | Wednesday | News
Amgen Announces Promising Phase 2 Results for MariTide, Showing Significant Weight Loss and Cardiometabolic Improvements

Amgen (NASDAQ:AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly...

November 27, 2024 | Wednesday | News
Roche to Acquire Poseida Therapeutics in Strategic Move to Advance Off-the-Shelf CAR-T Cell Therapies

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida&r...

November 27, 2024 | Wednesday | News
Alnylam's Vutrisiran sNDA Accepted by FDA for Priority Review in ATTR-CM with March 2025 Decision Expected

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...

November 26, 2024 | Tuesday | News
GSK’s Blenrep Combination Therapy Accepted for FDA Review in Relapsed Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...

November 26, 2024 | Tuesday | News
AstraZeneca’s Truqap Combination Shows Significant Benefit in PTEN-Deficient Prostate Cancer in CAPItello-281 Phase III Trial

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with ...

November 26, 2024 | Tuesday | News
MSD Announces Positive Phase 3 ZENITH Study Results for WINREVAIR in Pulmonary Arterial Hypertension

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...

November 26, 2024 | Tuesday | News
West China Lecheng Hospital Launches Vorasidenib, First-in-Class Targeted Therapy for IDH-Mutant Glioma

It was announced that West China Lecheng Hospital has successfully introduced Vorasidenib for treatment at clinical practices, and the treatment began at o...

November 25, 2024 | Monday | News
Hanmi Pharmaceutical Showcases Promising Clinical Progress of BH3120 at SITC 2024 Conference

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical...

November 25, 2024 | Monday | News
Zevra Therapeutics Launches MIPLYFFA™, the First FDA-Approved Treatment for Niemann-Pick Disease Type C

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist&...

November 22, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close